54.9 F

NEMUS Bioscience Reaches Research Agreement with University of Mississippi

Photo from nemusbioscience.com.
Photo from nemusbioscience.com.

NEMUS Bioscience, Inc. announced the signing of a research agreement with the University of Mississippi (UM) to study and conduct research and development on cannabidiol (CBD) containing formulations.

John Hollister, CEO of NEMUS, said, “CBD has shown evidence of therapeutic activity in a variety of diseases, particularly those involving the nervous system, immune reactivity and inflammation. Determining effective means of administering this molecule was a primary goal for NEMUS this year and we are excited to commence further development with our partner, the University of Mississippi.”

NEMUS Bioscience, Inc. is a biopharmaceutical company located in Costa Mesa, California. Led by a team of executives with lengthy experience in biopharmaceutical products and early-stage drug development, the company researches on the development and commercialization of cannabis-based therapeutics for medical needs.

Brian Murphy, MD, chief medical officer of NEMUS, said, “When working with cannabinoids, it is important to develop therapies that enhance bioavailability in a predictable and safe way. This is a central tenet of our cannabinoid research program and underlies our objectives in the development of proprietary forms of CBD that could have multiple candidate routes of administration based on the disease state of the patient. Our next steps will be to prioritize medical indications where CBD will be effective using technology platforms developed by our partners at UM.”

NEMUS is utilizing certain proprietary technology at University of Mississippi to develop ways to use cannabis-based drugs for specific needs. It aims to optimize the clinical effects of such drugs while limiting potential adverse effects. NEMUS’s strategy will explore the use of natural and synthetic compounds, alone or in combination.

Dr. Mahmoud ElSohly, professor at National Center for Natural Products Research at UM and a leading global expert on cannabinoid chemistry, said, “The university is looking forward to advancing new formulations of CBD to meet serious medical conditions where non-psychotropic cannabinoids can play a significant role.”

The University of Mississippi is currently the only US entity authorized by the Federal government to cultivate cannabis on behalf of the federal government. The university also holds a DEA registration to conduct cannabis research and previously held DEA registrations to cultivate cannabis and manufacture extracts for the development of drug product candidates.

Dr. Soumyajit Majumdar, associate professor of pharmaceutics and drug delivery and associate dean for research in the School of Pharmacy, said, “The impact CBD has on multiple physiologic systems makes it an attractive candidate for medicinal development.”

“NEMUS is continuing our glaucoma and MRSA therapeutic development programs and is looking forward to incorporating CBD into our product portfolio where appropriate,” said Hollister.

NEMUS Bioscience and the University of Mississippi entered into a research and in-licensing collaboration agreement in 2014.

For more information, visit www.nemusbioscience.com.

Most Popular

Recent Comments

scamasdscamith on News Watch Ole Miss
Frances Phillips on A Bigger, Better Student Union
Grace Hudditon on A Bigger, Better Student Union
Millie Johnston on A Bigger, Better Student Union
Binary options + Bitcoin = $ 1643 per week: https://8000-usd-per-day.blogspot.com.tr?b=46 on Beta Upsilon Chi: A Christian Brotherhood
Jay Mitchell on Reflections: The Square
Terry Wilcox SFCV USA RET on Oxford's Five Guys Announces Opening Date
Stephanie on Throwback Summer
organized religion is mans downfall on VP of Palmer Home Devotes Life to Finding Homes for Children
Paige Williams on Boyer: Best 10 Books of 2018
Keith mansel on Cleveland On Medgar Evans